Eliminate HIV

Ending the HIV epidemic as a public health threat is now a real possibility.

Globally, an estimated 36.7 million people were living with HIV, with 46 percent on life-saving antiretroviral treatment, according to the World Health Organization.

In Australia, more than 26,400 people were living with HIV in 2016 and according to annual HIV surveillance data more than 10 percent were unaware of their HIV-positive status.

The goals of our Eliminate HIV program include:

To facilitate reductions in new HIV infections in Australia and internationally through an improved understanding of the major drivers of transmission.
To work towards HIV elimination by addressing key barriers to the implementation of evidence-based HIV prevention programs, and expanding access to HIV diagnosis and treatment.
Use basic, discovery and translational research to develop, trial and implement new strategies and tools that assist in the prevention, diagnosis and treatment of HIV.

Contact Details

Chad Hughes

Deputy Program Director, Disease Elimination; Acting Regional Director, Mekong

Telephone

+61392822214

Email

chad.hughes@burnet.edu.au

Projects

A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression
Investigating a novel plasma biomarker's potential for identifying gut leakage.
A GIFT (Genital Inflammation Test) for HIV Prevention
Developing a biomarkers point-of-care test to identify women with genital inflammation who are at high risk of HIV acquisition
A novel gel for targeting vaginal inflammation to prevent HIV transmission
Developing an intravaginal gel delivering a vaginal microbiota metabolite.
ACCESS: STI and BBV surveillance system
ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
Antimicrobial and immune modulatory effects of vaginal microbiota metabolites
Determining the role of vaginal microbiota metabolites in activating HIV and other STIs.
Broadly neutralising anti-HIV antibodies and Fc Receptor function
Defining the properties of anti-HIV antibodies for vaccine development and protection of pregnant women.
co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
Community-Based Rapid HIV Testing Services
Evaluating a multi-site rapid HIV testing trial in South Australia and rural site in Bendigo, Victoria.
DARE C: ATAHC II Substudy
DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
Decision science using Optima
Research and applications across disease areas to improve allocative efficiency.
Depo Provera and Beyond
Understanding the Impact of Lower Dose Medroxyprogesterone Acetate and Long-Acting Contraceptives on Female Genital Tract Microbiome and Immunology
Developing new HIV disease progression tests
This project will develop prognostic tools to identify HIV+ persons at risk of rapid disease progression.
Development of a novel prophylactic vaccine candidate for HIV-1
A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission.
Development of hydrogel based intravaginal drug delivery device
Developing an intravaginal ring to deliver a microbiota metabolite.
Getting to the heart of cardiovascular disease in HIV
Investigating the pathogenesis of cardiovascular disease in HIV infection and identifying clinically useful predictors and therapies.
HIV Prevention Cohort
Online cohort study of gay men in Victoria monitoring community-level change.
Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility
Determining the role of a vaginal microbiota metabolite in enhancing the mucosal barrier to prevent HIV transmission.
Mucosal injury from sexual contact (MISC)
Understanding the biological and socio-behavioural risk factors for HIV acquisition in South African adolescents.
Predicting quality and potency of monoclonal and natural antibodies
Rapid, simple and scalable assays for predicting antibody potency.
PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)
Burnet is playing a crucial role in monitoring the outcomes of the PrEPX trial in Victoria.
PRONTO! Rapid HIV point-of-care testing in Victoria
The first rapid HIV test service in Victoria targeting gay men and men who have sex with men.
SHARP: Sexual Health And Risk Prevention Study
Assessing responses to HIV prevention measures among Australian MSM.
Sustainability of HIV Services for Key Populations in Asia Program (SKPA)
The SKPA Global Fund HIV grant aims to promote sustainable services for key populations at scale to stop HIV transmissions and AIDS related deaths in PNG by 2030.
TAIPAN: HIV cascade surveillance
Internationally novel project to create a linked surveillance system to monitor the HIV cascade for gay men
Targeting HIV-infected macrophages to achieve an HIV cure
Optimising methods to target and kill HIV-infected macrophages using Natural Killer cells.
Targeting novel sites on reverse transcriptase for HIV treatment and prevention
Discovering a new HIV drug class.
The persistence of HIV in monocytes and macrophages
Investigating the size and characteristics of the HIV reservoir in monocytes and macrophages that persists despite anti-HIV therapy.
The role of female genital tract microbial function in inflammation and HIV infection risk.
Using metaproteomics and in vitro models to evaluate the influence of microbial function on inflammation and HIV risk.

Latest News

11 March, 2020

HIV diagnosis and treatment for migrants lagging in Australia

A new Burnet study has identified significant gaps in the rates of HIV diagnosis and treatment among migrants and overseas-born gay and bisexual men.

11 February, 2020

Burnet's EVE-M team celebrating the International Day of Women and Girls in Science

A flagship Burnet project is aiming to revolutionise female sexual and reproductive health.

Upcoming Events

There are no upcoming events at present.

Our mission:

To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.

Contact Us

85 Commercial Road, Melbourne
VIC, 3004, Australia

E: reception@burnet.edu.au
T: +61 3 9282 2111

The Hub Site Map Careers

Disclaimer Privacy Policy Complaints Policy

This website was developed with the generous support of a donor.

Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.

Support Burnet’s COVID-19 emergency response

Support Our Work

Burnet Institute: Medical Research. Practical Action.

Equity through better health

Eliminate HIV